Mainz Biomed B.v. Stock

Price

Target price

/ Tradegate WKN: A3C6XX / Name: Mainz Biomed B.v. / Stock / ? /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Mainz Biomed B.v. Stock

Heavy losses for Mainz Biomed B.v. today as the stock fell by -€0.024 (-6.700%).

For the coming years our community has positive and negative things to say abot the Mainz Biomed B.v. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Debt" there were negative voices in the community.

What does Mainz Biomed B.v. do?

Pros and Cons of Mainz Biomed B.v. in the next few years

Pros

M***** P*******

G***** c******* t* c**********

B****

Cons

S********** s********

W********* I********* f** t** n*** y****

C******** o* t** e**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-10-30

Reviewing the financials for Mainz Biomed B.v., it's certain that they're experiencing challenging times. That fact jumps off the page as the company is reporting multimillion-dollar losses in EBITDA and rather high negative returns on their assets and equity. However, the revenue of just over $789,000 for a biomedical company suggests a move in the right direction. Still, the overall financial performance tells a story of a company that is yet to break even.

Revenue Progress: The QuarterlyRevenueGrowthYOY reported is fairly impressive at 0.788 or 78.8% year-on-year. The timely realization of income like this demonstrates potential, suggesting progress toward profitability if costs can be controlled.

Book Value: The reported BookValue of 0.331 implies that the company has some assets, potentially intellectual in nature, backing up its valuation. Assets like patents or proprietary technology might be valuable but difficult to monetize in the early stages of a biomed venture.

Feedback